Hansen Pharmaceutical(SZ:002412)2024-10-10 12:47Financial Performance - The company has raised a total of 68.02 million yuan since its listing and has distributed cash dividends amounting to 48.47 million yuan [3] - The company aims to maintain a cash dividend policy while balancing business development needs and shareholder demands [4] Market Strategy - The company is focused on increasing R&D investment, particularly in new product development and the consistency evaluation of generic drugs [2] - The management is committed to enhancing operational performance and improving company value through effective management practices [4] Shareholder Engagement - The company has implemented various channels for investor communication, including an investor hotline, online platforms, and performance briefings [5] - The management is attentive to shareholder feedback regarding stock buybacks and dividend policies, indicating a willingness to consider these suggestions [3][4] Future Plans - The company plans to extend its operations into the health and wellness sector, leveraging its existing strengths in traditional Chinese medicine [6] - A health industry park project has been initiated, focusing on the cultivation and processing of medicinal herbs, aiming to integrate various health-related services [6] Market Conditions - The company's stock price has remained below 10 yuan, influenced by macroeconomic factors, industry expectations, and market sentiment [4] - The management acknowledges the challenges posed by the current market environment and is focused on long-term stability and growth [4]